Dr. Vahan Kassabian oversees the use of Xofigo at Advanced Prostate Cancer Center
Georgia Urology, the largest urology practice in the Southeast, stays on the frontline in the battle against prostate cancer by equipping its physicians with the latest and greatest treatment options. Among the arsenal is Xofigo, manufactured by Bayer, an effective drug in the fight against advanced prostate cancer.
Georgia Urology uses Xofigo to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. It is for men whose prostate cancer has spread to the bone with symptoms, but not to other parts of the body.
“Xofigo contains radioactive material that works by going to areas in the bones that are growing quickly, just like calcium does,” said Dr. Vahan Kassabian, who oversees Georgia Urology’s Advanced Prostate Cancer Center.
Bone metastases are one of those rapidly growing areas. Once at the metastases, Xofigo gives off a strong energy that travels a short distance. The energy has a deadly effect on the cancer cells in the bones, stamping out the disease while doing limited damage to nearby healthy cells.
In order to administer Xofigo, Georgia Urology created a hot lab –specially designed for the use of radioactive substances– at its Advanced Prostate Cancer Center. The staff underwent special training to offer this treatment option, and a radiologist remains present during administration. Georgia Urology’s first Xofigo treatment took place in March 2016. Since then, the practice has treated more than 20 patients with Xofigo.
“At Georgia Urology, we’ve seen this therapeutic agent significantly extend overall survival,” said Dr. Kassabian. “In fact, a pivotal study shows that Xofigo can help extend life by more than 30 percent versus placebo treated men.”
Georgia Urology’s Advanced Prostate Cancer, 5730 Glenridge Drive, Suite 200, Atlanta. 404-256-1844.